JP2016513097A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513097A5
JP2016513097A5 JP2015556938A JP2015556938A JP2016513097A5 JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5 JP 2015556938 A JP2015556938 A JP 2015556938A JP 2015556938 A JP2015556938 A JP 2015556938A JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5
Authority
JP
Japan
Prior art keywords
composition
albumin
composition according
paclitaxel
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015556938A
Other languages
English (en)
Japanese (ja)
Other versions
JP6388880B2 (ja
JP2016513097A (ja
Filing date
Publication date
Priority claimed from US13/791,841 external-priority patent/US9149455B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/072877 external-priority patent/WO2014123612A1/en
Publication of JP2016513097A publication Critical patent/JP2016513097A/ja
Publication of JP2016513097A5 publication Critical patent/JP2016513097A5/ja
Application granted granted Critical
Publication of JP6388880B2 publication Critical patent/JP6388880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015556938A 2013-02-11 2013-12-03 メラノーマの治療方法 Active JP6388880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763391P 2013-02-11 2013-02-11
US61/763,391 2013-02-11
US13/791,841 US9149455B2 (en) 2012-11-09 2013-03-08 Methods of treating melanoma
US13/791,841 2013-03-08
PCT/US2013/072877 WO2014123612A1 (en) 2013-02-11 2013-12-03 Methods of treating melanoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017214523A Division JP6470381B2 (ja) 2013-02-11 2017-11-07 メラノーマの治療方法

Publications (3)

Publication Number Publication Date
JP2016513097A JP2016513097A (ja) 2016-05-12
JP2016513097A5 true JP2016513097A5 (Direct) 2017-01-12
JP6388880B2 JP6388880B2 (ja) 2018-09-12

Family

ID=51300036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015556938A Active JP6388880B2 (ja) 2013-02-11 2013-12-03 メラノーマの治療方法
JP2017214523A Active JP6470381B2 (ja) 2013-02-11 2017-11-07 メラノーマの治療方法
JP2019006038A Withdrawn JP2019056014A (ja) 2013-02-11 2019-01-17 メラノーマの治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017214523A Active JP6470381B2 (ja) 2013-02-11 2017-11-07 メラノーマの治療方法
JP2019006038A Withdrawn JP2019056014A (ja) 2013-02-11 2019-01-17 メラノーマの治療方法

Country Status (13)

Country Link
EP (1) EP2953622B1 (Direct)
JP (3) JP6388880B2 (Direct)
KR (1) KR102148551B1 (Direct)
CN (2) CN105120859B (Direct)
BR (1) BR112015019064A8 (Direct)
CA (1) CA2900668A1 (Direct)
ES (1) ES2872328T3 (Direct)
HK (1) HK1218506A1 (Direct)
IL (1) IL240388B (Direct)
MX (1) MX377729B (Direct)
NZ (1) NZ630239A (Direct)
WO (1) WO2014123612A1 (Direct)
ZA (1) ZA201505956B (Direct)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180050426A (ko) 2010-03-29 2018-05-14 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
KR20140107417A (ko) 2011-12-14 2014-09-04 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014159171A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
SG11201507234UA (en) 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
BR112016030965A2 (pt) * 2014-10-06 2017-08-22 Mayo Found Medical Education & Res Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
HUE070408T2 (hu) 2015-06-29 2025-06-28 Abraxis Bioscience Llc Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra
JP6921802B2 (ja) * 2015-08-18 2021-08-18 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research キャリア結合剤組成物およびそれを作製および使用する方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
RU2019109209A (ru) 2016-09-01 2020-10-05 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способ и композиции для направленного на мишень воздействия при лечении т-клеточных видов рака
JP2019526587A (ja) 2016-09-06 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research Pd−l1を発現する癌を処置する方法
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
BR112020005814A2 (pt) 2017-10-03 2020-09-24 Crititech, Inc. administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX383644B (es) 2005-02-18 2025-03-14 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス, エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
CA2686736A1 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
US20120128732A1 (en) * 2008-12-11 2012-05-24 Vuong Trieu Combinations and modes of administration of therapeutic agents and combination therapy
WO2012048223A1 (en) * 2010-10-08 2012-04-12 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2016513097A5 (Direct)
JP2016513075A5 (Direct)
JP2018111728A5 (Direct)
JP2016512513A5 (Direct)
JP2013503174A5 (Direct)
JP2016506908A5 (Direct)
JP2016512506A5 (Direct)
JP2010529025A5 (Direct)
JP2012506448A5 (Direct)
JP2016505018A5 (Direct)
NZ604029A (en) Methods of treating bladder cancer
JP2017226708A5 (Direct)
HRP20211062T1 (hr) Metode liječenja raka gušterače koje uključuju paklitaksel i gemcitabin
JP2010514787A5 (Direct)
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
JP2011511072A5 (Direct)
EA200701195A1 (ru) Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением
JP2016515586A5 (Direct)
JP2013527233A5 (Direct)
JP2018508593A5 (Direct)
JP2019507797A5 (Direct)
JP2017503842A5 (Direct)
HRP20250141T1 (hr) Nanočestice koje sadrže sirolimus i albumin za upotrebu u liječenju tumora epiteloidnih stanica
RU2017134443A (ru) Способ лечения с применением традипитанта
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors